Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28191960 | 0.85 | TDP1 (0.52) | ALDH1A1KMT2AATMSMN1; SMN2LMNA | |
| SCHEMBL501720 | 0.84 | ATM (0.76) | ALDH1A1KMT2AMAPTATMGAA | |
| SCHEMBL5350446 | 0.83 | ATM (0.74) | ALDH1A1KMT2AMAPTATMGAA | |
| SCHEMBL14369843 | 0.83 | ATM (0.74) | ALDH1A1KMT2AMAPTATMGAA | |
| SCHEMBL27467014 | 0.81 | KDM4E (0.63) | ALDH1A1KMT2AMAPTATMGAA | |
| SCHEMBL27781998 | 0.81 | POLB (0.59) | ALDH1A1KMT2ALMNAHIF1APOLB | |
| SCHEMBL14127629 | 0.81 | TDP1 (0.47) | NPC1ALDH1A1KMT2AMAPTGAA | |
| SCHEMBL8140389 | 0.81 | SIGMAR1 (0.51) | ALDH1A1KMT2AMAPTLMNAHIF1A | |
| SCHEMBL27676405 | 0.80 | ATM (0.48) | NPC1ALDH1A1KMT2AMAPTATM | |
| SCHEMBL14361229 | 0.80 | ALDH1A1 (0.54) | NPC1ALDH1A1KMT2AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104755460-B | N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug | 株式会社钟根堂 | 2017-05-10 | — | — | CN | claimed |
| US-4305940-A | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | B.B.R. BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1981-12-15 | — | — | US | claimed |
| EP-4662213-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168016-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| EP-3174868-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | Nuevolution A/S (DK) | 2017-06-07 | — | — | EP | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| WO-2016016316-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2016-02-04 | — | — | WO | disclosed |
| CN-102014635-B | Difluoro-containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2015-12-16 | — | — | CN | disclosed |
| CN-101180266-B | As the alpha ketoamide compounds of cystatin | Vero Bay (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-101969973-B | Inhibitors of cathepsin B | VIROBAY INC | 2015-07-22 | — | — | CN | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1364155-A | N-Cyanomethyl amides as protease inhibitors | AXYS PHARM INC (US) | 2002-08-14 | — | — | CN | disclosed |
| CN-1350534-A | Substituted bicyclic heteroaryl compounds as integrin antagonists | AVENTIS PHARMA LTD (GB) | 2002-05-22 | — | — | CN | disclosed |
| CN-1345314-A | Amine derivatives as protease inhibitors | AXYS PHARM INC (US) | 2002-04-17 | — | — | CN | disclosed |
| CN-1327443-A | Substituted anilide compounds | ARVENTIS PHARMACEUTICALS CO LT (GB) | 2001-12-19 | — | — | CN | disclosed |
| CN-1323295-A | Azabicyclic compounds for modulating cell adhesion inhibition | AVENTIES PHARMACEUTICAL LTD (GB) | 2001-11-21 | — | — | CN | disclosed |
| CN-1283181-A | Substituted beta-alanines | AWONGTISFAMA CO LTD (GB) | 2001-02-07 | — | — | CN | disclosed |
| CN-1273584-A | Imidazolyl-cyclic acetals | RHONE POULENC RORER LTD (GB) | 2000-11-15 | — | — | CN | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |